$SLXN News

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Announces First Patient Dosed Phase 2/3 Clinical Trial Evaluating Lead Candidate, SIL204, In Patients With Locally Advanced Pancreatic Cancer

Silexion Therapeutics Announces Exercise of Warrants

Silexion Therapeutics To Raise $837K Via Exercise Of ~3.217M Series E Warrants At $0.2603/Share

Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On

Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Receives Approval From Germany's Federal Institute For Drugs And Medical Devices To Start Its Planned Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer

Silexion Therapeutics to Attend BIO International Convention 2026

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Silexion Therapeutics Announces 1-For-10 Reverse Share Split Of Ordinary Shares, Effective May 28

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Silexion Therapeutics Q1 EPS $(0.85) Beats $(1.29) Estimate

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds